Vera Therapeutics, Inc. (VERA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vera Therapeutics, Inc. (VERA) Healthcare & Pipeline Overview

Vera Therapeutics, Inc., a clinical-stage biotechnology firm, is focused on developing and commercializing treatments for immunological diseases. Its lead candidate, atacicept, targets immunoglobulin A nephropathy and is currently in Phase IIb trials, positioning the company in the competitive biotechnology landscape with a focus on innovative therapies.

What Is the Investment Thesis for VERA?

Vera Therapeutics presents a compelling investment thesis centered on its innovative pipeline targeting immunological diseases. The primary value driver is atacicept, currently in Phase IIb trials for IgAN, a market with substantial unmet needs. Positive trial results could drive significant stock appreciation. The company's secondary asset, MAU868, targeting BK viremia, offers additional upside potential. Key risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $2.24B and a beta of 1.17, Vera Therapeutics exhibits moderate volatility. Upcoming clinical trial data releases will be critical catalysts. Successful development and commercialization could establish Vera Therapeutics as a leader in the immunological disease treatment landscape.

Based on FMP financials and quantitative analysis

VERA Key Highlights

Vera Therapeutics' lead product candidate, atacicept, is in Phase IIb clinical trials for immunoglobulin A nephropathy (IgAN).

• The company is also developing MAU868, a monoclonal antibody, for the treatment of BK viremia infections, currently in Phase 2 clinical trials.
• Vera Therapeutics changed its name from Trucode Gene Repair, Inc. in April 2020, reflecting a strategic shift towards immunological therapies.
• The company has a market capitalization of $2.24B, indicating substantial investor interest in its pipeline.
• Vera Therapeutics employs 152 individuals, reflecting its operational scale as a clinical-stage biotechnology company.

Who Are VERA's Competitors?

VERA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VERA's Key Strengths?

Innovative pipeline targeting unmet needs in immunology.

• Lead product candidate in Phase IIb clinical trials.
• Experienced management team with expertise in drug development.
• Strong intellectual property protection for its drug candidates.

What Are VERA's Weaknesses?

Reliance on successful clinical trial outcomes.

• Limited commercial infrastructure as a clinical-stage company.
• High cash burn rate associated with drug development.
• Vulnerability to regulatory setbacks and competition.

What Could Drive VERA Stock Higher?

Data readout from the Phase IIb clinical trial of atacicept for IgAN.

• Initiation of Phase 3 clinical trials for atacicept, pending Phase IIb results.
• Progress in the Phase 2 clinical trial of MAU868 for BK viremia.
• Potential for strategic partnerships or collaborations to accelerate development.
• Regulatory milestones and interactions with the FDA.

What Are the Key Risks for VERA?

Negative return on equity (-84.1%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Delays in regulatory approval processes.
• Competition from other companies developing treatments for immunological diseases.
• High cash burn rate and reliance on future financing.
• Intellectual property challenges or patent disputes.

What Are the Growth Opportunities for VERA?

• Atacicept for IgAN Treatment: The primary growth opportunity lies in the successful development and commercialization of atacicept for immunoglobulin A nephropathy (IgAN). Positive Phase IIb trial results could lead to accelerated regulatory approval and rapid market penetration. Vera Therapeutics' competitive advantage lies in atacicept's targeted mechanism of action, potentially offering superior efficacy and safety compared to existing therapies. Timeline for potential FDA approval is estimated within the next 3-5 years.
• MAU868 for BK Viremia: Development of MAU868 for BK viremia infections presents another significant growth avenue. BK viremia is a common complication in kidney transplant recipients, creating a substantial market for effective treatments. Successful Phase 2 trial outcomes could pave the way for regulatory approval and commercialization. Vera Therapeutics' monoclonal antibody approach offers a targeted solution to combat BK viremia, potentially reducing the need for more aggressive immunosuppression. The market size for BK viremia treatments is projected to grow as the number of kidney transplants increases.
• Expansion into New Immunological Indications: Vera Therapeutics can leverage its expertise in immunological disease to expand its pipeline into new therapeutic areas. Identifying and developing treatments for other autoimmune disorders or inflammatory conditions could diversify the company's revenue streams and reduce reliance on its lead product candidates. This expansion strategy could involve in-licensing promising drug candidates or initiating internal research and development programs. The market for autoimmune disease treatments is vast and growing, offering numerous opportunities for Vera Therapeutics to capitalize on its scientific capabilities.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of Vera Therapeutics' pipeline. Collaborations can provide access to additional funding, expertise, and resources, enhancing the company's ability to navigate the complex regulatory landscape and bring its products to market. Partnerships could also involve co-development agreements or licensing deals, generating upfront payments and milestone payments for Vera Therapeutics.
• Geographic Expansion: Expanding its commercial operations beyond the United States represents a long-term growth opportunity for Vera Therapeutics. Entering international markets, such as Europe and Asia, could significantly increase the company's revenue potential. This expansion would require establishing local regulatory expertise, building sales and marketing infrastructure, and adapting its products to meet the specific needs of different patient populations. Geographic expansion could be achieved through direct sales or partnerships with local distributors.

What Threats Does VERA Face?

• Clinical trial failures or delays.
• Competition from established pharmaceutical companies.
• Changes in regulatory requirements.
• Economic downturn impacting healthcare spending.

What Are VERA's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Clinical trial data demonstrating efficacy and safety.
• Specialized expertise in immunology and drug development.
• Established relationships with key opinion leaders and researchers.
• First-mover advantage in targeting specific immunological diseases.

What Does VERA Do?

Vera Therapeutics, Inc., established in 2016 and headquartered in Brisbane, California, is a clinical-stage biotechnology company dedicated to developing and commercializing transformative treatments for patients suffering from serious immunological diseases. Originally incorporated as Trucode Gene Repair, Inc., the company rebranded to Vera Therapeutics in April 2020, signaling a refined focus on immunological therapies. The company's lead product candidate, atacicept, is a self-administered subcutaneous injection currently in Phase IIb clinical trials for the treatment of immunoglobulin A nephropathy (IgAN), a kidney disease. Atacicept is a fusion protein designed to reduce levels of IgA and may offer a targeted approach to treating IgAN. In addition to atacicept, Vera Therapeutics is also developing MAU868, a monoclonal antibody in Phase 2 clinical trials for the treatment of BK viremia infections, a significant complication in kidney transplant recipients. Vera Therapeutics aims to address unmet medical needs in immunological diseases through innovative research and development, positioning itself as a key player in the biotechnology sector.

What Products and Services Does VERA Offer?

• Develops treatments for immunological diseases.
• Focuses on commercializing therapies for patients with serious conditions.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Utilizes fusion protein technology for targeted therapies.
• Develops monoclonal antibodies for specific disease targets.
• Aims to address unmet medical needs in the field of immunology.
• Seeks regulatory approval from agencies like the FDA for its products.

How Does VERA Make Money?

• Develops and patents novel therapeutic candidates.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval for commercialization.
• May partner with larger pharmaceutical companies for distribution and sales.
• Generates revenue through product sales upon regulatory approval.

What Industry Does VERA Operate In?

Vera Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory oversight, and substantial financial risk. The market for immunological disease treatments is expanding, driven by an aging population and increased prevalence of autoimmune disorders. Competition is intense, with established pharmaceutical giants and emerging biotech firms vying for market share. Vera Therapeutics' focus on IgAN and BK viremia positions it in niche markets with unmet needs, potentially offering a competitive advantage. The biotechnology industry is subject to stringent regulatory requirements, with the FDA playing a crucial role in drug approval processes.

Who Are VERA's Key Customers?

• Patients suffering from immunoglobulin A nephropathy (IgAN).
• Patients with BK viremia infections, particularly kidney transplant recipients.
• Healthcare providers who prescribe and administer Vera Therapeutics' treatments.
• Hospitals and clinics that utilize Vera Therapeutics' products.
• Potential future patients with other immunological diseases.

Company Profile

Vera Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Brisbane, US. The company is led by CEO Marshall Fordyce. VERA has traded publicly since 2021.

Vera Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.07 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Vera Therapeutics, Inc. stands at -84.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -75.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.4%, the inverse of the P/E and a quick read on earnings relative to price.

VERA Valuation & Market Position

With a $2.24B market cap, Vera Therapeutics, Inc. sits in the mid-cap segment of the market. Relative to its peer group, VERA's quantitative score of 45/100 is below the peer average of 80/100.

Vera Therapeutics, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 12.1% below estimates on average.

Wall Street analysts project Vera Therapeutics, Inc. revenue of about $32.1M for fiscal 2026, with EPS near $-6.19. The estimate reflects 8 contributing analysts.

VERA Financials

VERA Latest News

VERA Analyst Consensus

VERA MoonshotScore

VERA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources